|
Volumn 247, Issue 6, 2000, Pages 19-22
|
What has changed with riluzole?
a a a |
Author keywords
Glutamate; Riluzole; Sodium channel; Therapeutic trials
|
Indexed keywords
GABAPENTIN;
GLUTAMATE RECEPTOR;
PLACEBO;
RILUZOLE;
GLUTAMIC ACID;
NEUROPROTECTIVE AGENT;
ADULT;
AMYOTROPHIC LATERAL SCLEROSIS;
CLINICAL RESEARCH;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ACTIVITY;
DRUG MECHANISM;
FATIGUE;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MUSCLE STRENGTH;
OXIDATIVE STRESS;
PATHOGENESIS;
PATIENT CARE;
PRIORITY JOURNAL;
RESPIRATORY TRACT DISEASE;
RIGIDITY;
ANIMAL;
METABOLISM;
PHYSIOLOGY;
RESEARCH;
TREATMENT OUTCOME;
TRENDS;
AGED;
AMYOTROPHIC LATERAL SCLEROSIS;
EXCITATORY AMINO ACID ANTAGONISTS;
FEMALE;
GLUTAMIC ACID;
HUMANS;
MALE;
MIDDLE AGED;
NEUROPROTECTIVE AGENTS;
RILUZOLE;
ANIMALS;
RESEARCH;
TREATMENT OUTCOME;
|
EID: 0034517831
PISSN: 09391517
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (33)
|
References (19)
|